Cefpodoxime Proxetil
- PDF / 300,910 Bytes
- 22 Pages / 504 x 720 pts Page_size
- 89 Downloads / 125 Views
Paediatric Drugs 2001; 3 (2): 137-158 1174-5878/01/0002-0137/$22.00/0 © Adis International Limited. All rights reserved.
Cefpodoxime Proxetil A Review of its Use in the Management of Bacterial Infections in Paediatric Patients Bret Fulton and Caroline M. Perry Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: S.L. Block, Kentucky Pediatric Research, Incorporated, Bardstown, Kentucky, USA; R.A. Damoiseaux, Department of General Practice, University Medical Centre, Universiteitsweg 100, Utrecht, The Netherlands; J.J. Haddad, Babies Hospital North 501, New York, New York, USA; D.A. Kafetzis, P&A Kyriakou Children’s Hospital, Thibon and Lebadias, Athens, Greece; G.L. Kearns, Division of Pediatric Pharmacology & Medical Toxicology, Children’s Mercy Hospital, University of Missouri, Kansas City, Missouri, USA; Y-C Liu, Section of Infectious Diseases, Department of Medicine, Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan; T. Terui, Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan. Data Selection Sources: Medical literature published in any language since 1966 on cefpodoxime-proxetil, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International, Auckland, New Zealand). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘cefpodoxime proxetil’ or ‘CPDX PR’ or ‘CS 807’ or ‘U 76252’ and (‘pediatrics’ or ‘children’). EMBASE search terms were ‘cefpodoxime proxetil’ or ‘CPDX PR’ or ‘CS 807’ or ‘U 7652’ and (‘pediatrics’ or ‘children’). AdisBase search terms were ‘cefpodoxime-proxetil’ or ‘CS 807’ and (‘pediatrics’ or ‘children’). Searches were last updated 30 Jan 2001. Selection: Studies in children with infectious diseases who received cefpodoxime proxetil. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Cefpodoxime proxetil, antibiotic, cephalosporin, infectious diseases, paediatric, pharmacodynamics, pharmacokinetics, therapeutic use.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Scope of the Review . . . . . . . . . . . . . . . . . . . . . . . 2. Antibacterial Activity . . . . . . . . . . . . . . . . . . . . . . 2.1 Aerobic Gram-Positive Bacteria . . . . . . . . . . . . . 2.2 Aerobic Gram-Negative Bacteria . . . . . . . . . . . . 2.3 Anaerobic Bacteria . . . . . . . . . . . . . . . . . . . . 2.4 Stability Against β-Lactamases . . . . . . . . . . . . . . 2.5 Pharmacodynamic/Pharmacokinetic Considerations 3. Pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . 3.1 Absorption . . . . . . . . . . . . . . . . . . . . . . . . . . 3.2 Distribution
Data Loading...
